Neutralisation

ProMIS Neurosciences and collaborator BC Neuroimmunology announce significant progress on development of highly accurate antibody test for COVID-19

Retrieved on: 
Wednesday, June 17, 2020

Incorporation of ProMIS proprietary peptide antigens in the next phase of development is anticipated to support determination of whether or not antibodies detected in the serology assay possess virus neutralizing activity.

Key Points: 
  • Incorporation of ProMIS proprietary peptide antigens in the next phase of development is anticipated to support determination of whether or not antibodies detected in the serology assay possess virus neutralizing activity.
  • Starting next year, and throughout 2021 and beyond, we anticipate that billions of people will receive COVID-19 vaccines, stated ProMIS executive chairman, Eugene Williams.
  • ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
  • To learn more about COVID-19 antibody testing listen to the podcast, Saving Minds, at iTunes or Spotify .

AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19

Retrieved on: 
Friday, June 5, 2020

AbbVie (NYSE:ABBV), Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) today announced they have entered into a collaboration to develop a novel antibody therapeutic to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus.

Key Points: 
  • AbbVie (NYSE:ABBV), Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) today announced they have entered into a collaboration to develop a novel antibody therapeutic to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus.
  • The focus of the collaboration is on advancing the fully human, neutralizing antibody 47D11 discovered by UU, EMC and HBM and recently reported in Nature Communications .
  • AbbVie will receive an option to exclusively license the antibody from the three parties for therapeutic clinical development and commercialization worldwide.
  • The antibody discovery, published online on May 4 in Nature Communications, targets a conserved region of the virus spike protein.

AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19

Retrieved on: 
Friday, June 5, 2020

and UTRECHT, Netherlandsand ROTTERDAM, Netherlands and SUZHOU, China, June 5, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) today announced they have entered into a collaboration to develop a novel antibody therapeutic to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus.

Key Points: 
  • and UTRECHT, Netherlandsand ROTTERDAM, Netherlands and SUZHOU, China, June 5, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) today announced they have entered into a collaboration to develop a novel antibody therapeutic to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus.
  • The focus of the collaboration is on advancing the fully human, neutralizing antibody 47D11 discovered by UU, EMC and HBM and recently reported in Nature Communications .
  • AbbVie will receive an option to exclusively license the antibody from the three parties for therapeutic clinical development and commercialization worldwide.
  • The antibody discovery, published online on May 4 in Nature Communications, targets a conserved region of the virus' spike protein.

Memo Therapeutics AG Identifies Potent SARS-CoV-2-Neutralizing Antibodies From the Blood of Recovered COVID-19 Patients

Retrieved on: 
Thursday, June 4, 2020

The selection criteria identified patients who had demonstrated a clinical course of COVID-19 indicative of a particularly potent antibody response.

Key Points: 
  • The selection criteria identified patients who had demonstrated a clinical course of COVID-19 indicative of a particularly potent antibody response.
  • Blood samples were collected from the clinically selected donors and used with MTxs microfluidic DROPZYLLA discovery platform to identify SARS-CoV-2-neutralizing antibodies.
  • Dr. Karsten Fischer, CEO of Memo Therapeutics, said: The identification of SARS-CoV-2-neturalizing antibodies could be a game changer in how we tackle the global COVID-19 pandemic.
  • Memo Therapeutics AG (MTx) is an innovator in the field of antibody discovery and immune repertoire analysis.

GenScript Files for Emergency Use Authorization of Rapid SARS-CoV-2 Neutralization Antibody Detection Kit

Retrieved on: 
Wednesday, June 3, 2020

PISCATAWAY, N.J., June 3, 2020 /PRNewswire/ -- GenScript Biotech Corp ., the world's leading research reagent provider, announced today that the company has filed for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) to market its cPass SARS-CoV-2 Neutralization Antibody Detection Kit.

Key Points: 
  • PISCATAWAY, N.J., June 3, 2020 /PRNewswire/ -- GenScript Biotech Corp ., the world's leading research reagent provider, announced today that the company has filed for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) to market its cPass SARS-CoV-2 Neutralization Antibody Detection Kit.
  • Traditional virus neutralization tests require live virus and cells and must be performed in a biosafety containment facility staffed by highly skilled personnel, with results often taking days.
  • GenScript was founded in New Jersey, US in 2002 and listed on the Hong Kong Stock Exchange in 2015.
  • GenScript has a number of intellectual property rights and technical secrets, including more than 100 patents and over 270 patent applications.

Virna Therapeutics and University of Toronto Announce Licensing of Neutralizing Monoclonal Antibodies to Treat COVID-19

Retrieved on: 
Wednesday, May 27, 2020

Virna Therapeutics announces that they are partnering with University of Toronto to in-license neutralizing antibodies, to treat COVID-19.

Key Points: 
  • Virna Therapeutics announces that they are partnering with University of Toronto to in-license neutralizing antibodies, to treat COVID-19.
  • The crisis has presented severe challenges to global health but has also provided an opportunity to integrate advanced methods.
  • The founders of Virna Therapeutics include Dr. Sachdev Sidhu (Chief Scientific Officer), leader of the discovery and development process, Suresh K. Jain, PhD.
  • While Virna is researching multiple approaches for treating infectious diseases, their validated synthetic antibody technology is a powerful platform enabling efficient generation of fully-human monoclonal antibodies.

GenScript Biotech Announces CE-IVD for Its Neutralizing Antibody Test Kit of SARS-CoV-2 and COVID-19 Diagnostic Products

Retrieved on: 
Tuesday, May 26, 2020

GenScript Biotech Europe BV announced that it has obtained CE marking for its SARS-CoV-2 diagnostic products to be sold as an in vitro diagnostic (IVD).

Key Points: 
  • GenScript Biotech Europe BV announced that it has obtained CE marking for its SARS-CoV-2 diagnostic products to be sold as an in vitro diagnostic (IVD).
  • Among these products is the novel cPassTM SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit which detects the presence of neutralizing antibodies in an hour and does not require live biological materials or biosafety containment for testing.
  • This is a major advance in understanding the epidemiology of the disease and if individuals have developed neutralizing antibodies that may confer immunity.
  • GenScript went through the proof of concept research, product design, development, and optimization, working with Dr. Wang and the A*STAR team.

Centivax Antibodies Neutralize the Pandemic Coronavirus, Independently Confirmed by Three Research Laboratories (USAMRIID, Stanford, and UTMB/GNL)

Retrieved on: 
Monday, May 18, 2020

Today, three independent laboratories have confirmed that multiple Centivax antibody therapeutic candidates are potent neutralizers of the pandemic coronavirus.

Key Points: 
  • Today, three independent laboratories have confirmed that multiple Centivax antibody therapeutic candidates are potent neutralizers of the pandemic coronavirus.
  • Viral neutralization directly demonstrates that the antibodies are able to completely block the novel coronavirus from infecting human cells.
  • Independent validation is a cornerstone of good science, says Dr. Jacob Glanville, Founder, CEO, and President of Centivax and Distributed Bio.
  • When the pandemic struck, we were ready, notes Sarah Ives, Director of Contract Research at Distributed Bio and cofounder of Centivax.

STI-1499, A Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies

Retrieved on: 
Friday, May 15, 2020

These blocking antibodies were further tested for their ability to inhibit SARS-CoV-2 virus infection in an in vitro SARS-CoV-2 virus infection model pursuant to a preclinical testing agreement for COVID-19 therapeutic candidates that was previously announced on March 31, 2020 ( Sorrento Therapeutics ).

Key Points: 
  • These blocking antibodies were further tested for their ability to inhibit SARS-CoV-2 virus infection in an in vitro SARS-CoV-2 virus infection model pursuant to a preclinical testing agreement for COVID-19 therapeutic candidates that was previously announced on March 31, 2020 ( Sorrento Therapeutics ).
  • Among the antibodies showing neutralizing activity, one antibody stood out for its ability to completely block SARS-CoV-2 infection of healthy cells in the experiments.
  • STI-1499 completely neutralized the virus infectivity at a very low antibody dose, making it a prime candidate for further testing and development.
  • Sorrento has determined STI-1499 will likely be the first antibody in the antibody cocktail (COVI-SHIELD) it is developing, as recently announced.

XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients

Retrieved on: 
Friday, April 3, 2020

The testing technology will allow QualTex to identify blood that contains naturally neutralizing antibodies against the virus in patients who have recovered from COVID-19 (convalescent donors).

Key Points: 
  • The testing technology will allow QualTex to identify blood that contains naturally neutralizing antibodies against the virus in patients who have recovered from COVID-19 (convalescent donors).
  • XBiotech is a fully integrated, global biopharmaceutical company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies.
  • XBiotech currently is advancing a pipeline of therapies based on harnessing naturally occurring antibodies from patients with immunity to certain diseases.
  • XBiotechs True Human antibodies are the only available antibodies derived without modification from humans who possess natural immunity to certain diseases.